trial

Efficacy of Pregnenolone in Patients With Schizophrenia

NCTId NCT00615511
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 100 (actual)
Sponsored by Weill Medical College of Cornell University
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
100 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-06
Primary completion
2014-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Pregnenolone

Sponsors

Weill Medical College of Cornell UniversityLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Jason J Kim, MDPrincipal Investigator

Sites

3 total
Piscataway, United StatesNew York, United StatesWhite Plains, United States

Linked catalysts

1
Efficacy of Pregnenolone in Patients With Schizophrenia — primary completion2014-12

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE2
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Pregnenolone
drug
lead_sponsor
Weill Medical College of Cornell University
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Jason J Kim, MD
person